To test the efficacy of IL-2 inhibitors (Cyclosporine) compared to the Standard of care according to hospital protocol on COVID-19 patients concerning the clinical outcome (cytokines level, clinical improvement, and PCR of sARS-CoV-2 through the study period).~AIM:~The slow progression of the disease, improving survival among COVID-19 patients, and Standard assessment of patient improvement.~Standard assessment of patient improvement:~PCR-SARS-CoV-2 negative~No fever~No cytopenia (Hb ≥90 g/L, ANC ≥0.5x109/L, platelets ≥100x109/L) •~No hyperferritinemia ≥500 μg/L~(Decrease of IL2)
The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate